SLC34A2 and acute myeloid leukemia: Finally, in terms of the pathways underlying AML, we found both SLC34A2 and STEAP1 to be identified within significant KEGG (2016) terms in the standard versus low risk subgroup comparison in the TARGET database, as well as poor versus good risk and intermediate versus good risk comparisons in the TCGA database.